和譽-B(2256.HK)上限定價12.46港元/股 預計10月13日掛牌上市
格隆匯10月7日丨和譽-B(2256.HK)昨日招股結束,有消息稱最終以招股價上限12.46港元定價,集資17.54億港元。綜合多間券商數據,該股公開發售部分最終合共錄得5.6億元的孖展認購,若以公開發售部分集資1.75港億元計算,超額認購2.2倍。預期將於2021年10月13日在港交所主板掛牌上市。 和譽為一家臨牀階段的生物製藥公司,成立於2016年,致力於發現及開發創新且差異化的小分子腫瘤療法。截至目前,公司產品管線由14個專注於腫瘤學的候選藥物組成,包括五種處於臨牀階段的候選藥物,其候選產品主要為注重小分子腫瘤精準治療及小分子腫瘤免疫治療領域的小分子藥物。目前臨牀階段藥物開發的適應症包括肝細胞癌(HCC)、尿路上皮癌(UC)及胃癌(GC)等。 和譽此次公開發行的基石投資者包括LAV, UBS, BlackRock, Warburg Pincus, Temasek, OrbiMed, Vivo, Hudson Bay, Lake Bleu Prime, Janchor Partners, AIHC。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.